Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Effects of Pioglitazone in Reducing Atherosclerosis Progression and Neointima Volume in Type 2 Diabetic Patients: Prospective Randomized Study With Volumetric Intravascular Ultrasonography Analysis

  • You, Sung-Hye (Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Anam Hospital) ;
  • Kim, Beum-Suk (Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Anam Hospital) ;
  • Hong, Soon-Jun (Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Anam Hospital) ;
  • Ahn, Chul-Min (Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Anam Hospital) ;
  • Lim, Do-Sun (Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Anam Hospital)
  • Received : 2010.03.01
  • Accepted : 2010.05.08
  • Published : 2010.12.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Pioglitazone has been known for its anti-atherogenic effects. We compared the effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients. Subjects and Methods: This was a prospective, randomized single-blinded, 8-month follow-up study. Patients with significant coronary artery stenosis were randomly assigned to either pioglitazone (n=19) or placebo (n=18) following zotarolimus-eluting stent (ZES) implantation. Intravascular ultrasonography of the culprit vessel was performed from 20 mm distal and proximal to the stent at baseline. and at 8-month, and volumetric analysis was performed. Changes in inflammation markers, insulin resistance and lipid profile were compared. Results: Changes in atherosclerosis progression from baseline in the pioglitazone group was significantly lower than that of the placebo group (0.06${\pm}$0.73 vs. 1.16${\pm}$1.41 $mm^3$/mm, p=0.024, respectively), and neointima volume was significantly lower in the pioglitazone group compared to the placebo group (1.74${\pm}$0.93 vs. 2.42${\pm}$1.98 mm$^3$/mm, p=0.007, respectively). Homeostatic model assessment-index, interleukin-6, and tumor necrosis factor-${\alpha}$ levels were significantly lower in the pioglitazone group at 8 months. Adiponectin levels increased significantly only in the pioglitazone group. No significant differences in retinol binding protein-4 levels between the 2 groups were seen during the 8-month follow-up period. Conclusion: Compared to placebo, pioglitazone was associated with significant reduction in atherosclerosis progression and neointima formation in type 2 diabetic patients with ZES implantation.

Keywords

References

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31. https://doi.org/10.2337/diacare.21.9.1414
  2. Hong SJ, Kim MH, Ahn TH, et al. Comparison of the predictors of co-ronary restenosis after drug-eluting stent implantation in diabetic and nondiabetic patients. Korean Circ J 2007;37:530-7. https://doi.org/10.4070/kcj.2007.37.11.530
  3. Lee MG, Jeong MH, Ahn YK, et al. Comparison of clinical outcomes following acute myocardial infarctions in hypertensive patients with or without diabetes. Korean Circ J 2009;39:243-50. https://doi.org/10.4070/kcj.2009.39.6.243
  4. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31. https://doi.org/10.1016/j.jacc.2005.03.041
  5. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008;24:14-26. https://doi.org/10.1002/dmrr.790
  6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71. https://doi.org/10.1056/NEJMoa072761
  7. Forst T, Hohberg C, Fuellert SD, et al. Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adipo nectin and proinsulin intact levels and reduces intima media th-ickness in patients with type 2 diabetes. Horm Metab Res 2005;37: 521-7. https://doi.org/10.1055/s-2005-870322
  8. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31. https://doi.org/10.1161/01.CIR.0000165072.01672.21
  9. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73. https://doi.org/10.1001/jama.299.13.1561
  10. Tamborlane WV, Ahern J. Implications and results of the diabetes control and complications trial. Pediatr Clin North Am 1997;44:285-300. https://doi.org/10.1016/S0031-3955(05)70477-6
  11. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38. https://doi.org/10.1016/j.ahj.2005.09.015
  12. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-56. https://doi.org/10.1016/0092-8674(94)90006-X
  13. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 1998;101:22-32. https://doi.org/10.1172/JCI1244
  14. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 2007;120(9 Suppl 2):S18-25.
  15. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8. https://doi.org/10.1016/S0140-6736(06)69703-1
  16. Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995;18:747-53. https://doi.org/10.2337/diacare.18.6.747
  17. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997;20:1562-8. https://doi.org/10.2337/diacare.20.10.1562
  18. Shimizu H, Oh-I S, Tsuchiya T, Ohtani KI, Okada S, Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-$\alpha$ levels in Type 2 diabetic patients: a randomized study. Diabet Med 2006;23:253-7. https://doi.org/10.1111/j.1464-5491.2006.01776.x
  19. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91. https://doi.org/10.1126/science.7678183
  20. Desouza CV, Murthy SN, Diez J, et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zu-cker rats. J Cardiovasc Pharmacol Ther 2003;8:297-305. https://doi.org/10.1177/107424840300800407
  21. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. https://doi.org/10.1016/S0140-6736(05)67528-9

Cited by

  1. The Role of Intravascular Ultrasound in the Determination of Progression and Regression of Coronary Artery Disease vol.14, pp.2, 2010, https://doi.org/10.1007/s11883-012-0234-3
  2. Effects of a PPAR-γ (Peroxisome Proliferator-Activated Receptor-gamma) Activator on Flow-Mediated Brachial Artery Dilation and Circulating Level of microRNA-21 in Hypertensive Type 2 Diabetic Pa vol.19, pp.4, 2010, https://doi.org/10.5646/jksh.2013.19.4.99
  3. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients vol.6, pp.2, 2015, https://doi.org/10.1177/2042018815574229
  4. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials vol.9, pp.None, 2010, https://doi.org/10.1038/s41598-019-41854-2